Dynamic Changes in Bone Marrow Adiposity and the Role of Estrogen

Dynamic Changes in Bone Marrow Adiposity and the Role of Estrogen - Estrogen and changes in bone marrow adiposity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39889

Enrollment

Registered

2012-06-18

Start date

2012-07-18

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Part 1: no intervention Part 2: administration of estrogen (Zumenon 1dd 2 mg) during 14 days

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: female sex regular menstrual cycle and age 18 to 50 years OR 1-5 years postmenopausal

Exclusion criteria

Exclusion criteria: contraindications to MRI scanning use of bone-modifying or adipose tissue-modifying drugs use of hormonal contraception bone/adipose tissue/bone marrow diseases contraindications to estrogen treatment (history of hormone-sensitive cancer, VTE, unexplained vaginal bleeding, endometrial hyperplasia, endometriosis, arterial thrombo-embolic diseases, acute hepatic disease or liver enzyme disorders, porfyria or known hypersensitivity to components of zumenon)

Design outcomes

Primary

Measure	Time frame
The main study parameters are the dynamic changes in bone marrow adiposity as assessed by QCSI measurements and the correlation of these changes to changes in hormones involved in the menstrual cycle (follicle stimulating hormone, luteinizing hormone, progesterone and estradiol).	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)